Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VTX002
OPL-002 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| OPL-002 SDD 20 mg | EXPERIMENTAL | 20 mg SDD formulation of OPL-002 |
| OPL-002 5 mg Tablet | EXPERIMENTAL | 5 mg tablet formulation of OPL-002 |
| OPL-002 20 mg Tablet | EXPERIMENTAL | 20 mg tablet formulation of OPL-002 |
| Name | Type | Description |
|---|---|---|
| OPL-002 | DRUG | Spray dried dispersion and tablet formulation |
Inclusion Criteria: * Male or female (of non-childbearing potential only) between 18 and 55 years of age. * Females must be of non-childbearing potential and must have undergone one of the following sterilization procedures, and have official documentation, at least 6 months prior to the first dose...
OPL-002 is an investigational small molecule developed by Ventyx Biosciences, Inc. (ticker VTYX). It is in Phase 1 clinical development, and its specific therapeutic indications have not been disclosed. The program has completed one Phase 1 pharmacokinetic study in healthy volunteers.
OPL-002 is being developed by Ventyx Biosciences, Inc., which trades on the Nasdaq under the ticker VTYX. The company is the sponsor of the clinical program for this small molecule asset.
OPL-002 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this asset.
OPL-002 has been evaluated in one completed Phase 1 trial, NCT04451811, titled A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers. The study enrolled 12 healthy adult participants in the United Kingdom and used a controlled, randomized design without blinding.
The completed Phase 1 trial NCT04451811 evaluated the pharmacokinetic dose proportionality of OPL-002 in healthy volunteers. It enrolled 12 participants aged 18 years and older of all sexes in the United Kingdom. The study was randomized and controlled, and it has been completed.